Neoleukin Therapeutics (NASDAQ:NLTX) Stock Price Up 0.3% - Still a Buy?

Key Points

• NLTX shares rose 0.3% to $27.03 (intraday high $27.56) while trading volume surged ~445% to about 273,140 shares versus an average of 50,104.
• The company has a market cap of $254.03 million, trades above its 50- and 200-day moving averages (~$21.97 and $22.23) and shows a negative P/E of -8.69, reflecting its clinical-stage/loss-making status.
• Neoleukin is a clinical-stage biotech that uses computational protein engineering to create cytokine mimetics, with lead candidate NL-201 designed to engage IL-2/IL-15 receptors to enhance anti-tumor immune responses.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) rose 0.3% on Wednesday . The stock traded as high as $27.56 and last traded at $27.03. Approximately 273,140 shares traded hands during mid-day trading, an increase of 445% from the average daily volume of 50,104 shares. The stock had previously closed at $26.95.

Neoleukin Therapeutics Price Performance

The company's 50 day moving average is $21.97 and its two-hundred day moving average is $22.23. The firm has a market cap of $254.03 million, a P/E ratio of -8.69 and a beta of 1.11.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc is a clinical‐stage biotechnology company focused on the design and development of de novo protein therapeutics for the treatment of cancer and immune‐mediated diseases. Leveraging computational protein engineering, the company creates novel cytokine mimetics intended to provide targeted immune activation while minimizing the toxicities associated with natural cytokines. This platform is anchored by proprietary algorithms and structure‐based design tools that enable the rapid generation of therapeutic candidates with optimized stability, affinity and specificity.

The company's lead candidate, NL-201, is a next‐generation cytokine therapy designed to engage interleukin‐2 and interleukin‐15 receptors on immune effector cells, with the goal of enhancing anti‐tumor responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.